March 9, 2020 / 6:35 PM / 24 days ago

BRIEF-ViiV Presents Data From Phase III Study Of Investigational 2-Drug Regimen Of Cabotegravir

March 9 (Reuters) -

* VIIV HEALTHCARE - PRESENTED DATA FROM ITS PHASE III STUDY OF INVESTIGATIONAL 2-DRUG REGIMEN OF ITS CABOTEGRAVIR, JANSSEN’S RILPIVIRINE TO TREAT HIV

* VIIV -STUDY SHOWED 2DR OF CABOTEGRAVIR & RILPIVIRINE PROVIDED NON-INFERIOR EFFICACY & COMPARABLE SAFETY TO ORAL, 3 DRUG REGIMEN OF TRIUMEQ AT WEEK 96

* VIIV - NO NEW INSTANCES OF CONFIRMED VIROLOGIC FAILURE REPORTED BETWEEN WK 48 AND 96 AMONG INDIVIDUALS WHO RECEIVED CABOTEGRAVIR & RILPIVIRINE Source text: (reut.rs/2TTrCIW) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below